National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland 20892

11 studies enrolling now · 35 studies all time

What they study most

Adrenal Gland Pheochromocytoma, Advanced Alveolar Soft Part Sarcoma, Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Gastric Carcinoma

Studies at this site

• Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial — Recruiting now
• Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes — Recruiting now
• Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness — Recruiting now
• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial — Recruiting now
• Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma — Recruiting now
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — Recruiting now
• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial — Recruiting now
• Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors — Recruiting now
• Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers — Recruiting now
• Studying TAK-243 in Patients With Advanced Cancer — Recruiting now
• Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers — Recruiting now
• Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) — Running, not enrolling
• Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma — Running, not enrolling
• Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study — Running, not enrolling
• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma — Running, not enrolling
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer — Running, not enrolling
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors — Running, not enrolling
• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors — Paused
• CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer — Paused
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer — Running, not enrolling
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — Running, not enrolling
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines — Running, not enrolling
• Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma — Running, not enrolling
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — Running, not enrolling
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers — Running, not enrolling
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — Completed
• Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma — Running, not enrolling
• Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment — Running, not enrolling
• Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer — Running, not enrolling
• Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial — Running, not enrolling
• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial — Running, not enrolling
• Testing the Safety of CB-5339 in Patients With Cancer — Withdrawn before enrolling
• Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery — Completed
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — Completed
• MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations — Completed